Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Ravishankaran, Praveen ^a   Karunanithi, R ^b  

^a Institute of Orthopaedics and Traumatology   (India)

^b GANGA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CANCER STAGING; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR VOLUME; BLOOD; BREAST TUMOR; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; ROC CURVE; SURVIVAL RATE;

EID: 79952015621     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-18     Document Type: Article

References (21)

1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999, 161:182-187. 10.1016/S0022-5347(01)62092-5, 10037394.
2. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000, 6:2702-2706.
3. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol 2000, 164:722-725. 10.1016/S0022-5347(05)67289-8, 10953133.
4. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
5. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-356. 10.1038/bjc.1995.71, 2033591, 7841052.
6. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G. Serum levels of interleukin 6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 1998, 5:649-652.
7. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585-590. 10.1001/jama.291.5.585, 14762037.
8. Nozoe T, Mori E, Takahashi I, Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today 2008, 38:597-602. 10.1007/s00595-007-3680-8, 18612783.
9. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007, 107:114-117. 10.1016/j.ygyno.2007.06.001, 17617445.
10. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K. A prognostic index in primary breast cancer. Br J Cancer 1982, 45:361-366. 10.1038/bjc.1982.62, 2010939, 7073932.
11. Duffy SW, Taba'r L, Fagerberg G, Gad A, South MC, Day NE. Breast screening, prognostic factors and survival--results from the Swedish two county study. Br J Cancer 1991, 64:1133-1138. 10.1038/bjc.1991.477, 1977849, 1764377.
12. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 539 have been followed up for 15 years. Br J Cancer 1957, 11:359-377. 10.1038/bjc.1957.43, 2073885, 13499785.
13. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987, 56:489-492. 10.1038/bjc.1987.230, 2001834, 3689666.
14. Lonn U, Lonn S, Nilsson B, Stenkvist B. Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res Treat 1994, 29:237-245. 10.1007/BF00666477, 7914106.
15. Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002, 100:290-296. 10.1002/ijc.10478, 12115543.
16. Malmstrom P, Bendahl PO, Boiesen N, Brünner N, Idvall I, Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histological grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2000, 19:2010-2019.
17. Taba'r L, Chen HH, Duffy SW, Yen MF, Chiang CF, Dean PB, Smith RA. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet 2000, 355:429-433.
18. Taba'r L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening?. Cancer 1999, 86:449-462.
19. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271:736-741. 10.1074/jbc.271.2.736, 8557680.
20. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 2006, 12:4473-4477.
21. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 2007, 120:2600-2608. 10.1002/ijc.22599, 17304514.